Biocytogen Enters into Antibody Agreement with ADC Therapeutics
November 28 2022 - 9:47AM
Business Wire
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen",
HKEX: 02315) today announced that it has entered into an evaluation
and option agreement with ADC Therapeutics SA. Biocytogen will
grant ADC Therapeutics a license to evaluate Biocytogen’s
proprietary antibodies against three tumor targets, with an option
to license selected antibodies at a later date for global ADC
development and commercialization. Biocytogen reserves all global
rights for these antibodies beyond ADC development. Biocytogen will
receive an upfront payment. For each option exercised, Biocytogen
will be entitled to an option-exercise fee, and development and
commercial milestone payments, which potentially total tens of
millions of US dollars, as well as single-digit royalties on net
sales.
Under the agreement, Biocytogen will provide ADC Therapeutics
with monoclonal and/or biparatopic antibodies directed against
three tumor targets, generated through Biocytogen’s Project
Integrum (also called RenMiceTM HiTS Platform). ADC Therapeutics
will carry out feasibility studies and be responsible for further
development and commercialization of the ADC products if the
company exercises an option.
“ADC Therapeutics is a leader in the development and
commercialization of ADCs. We believe this collaboration with ADC
Therapeutics will underscore the value of Biocytogen’s proprietary
antibody discovery and screening platforms,” said Dr. Yuelei Shen,
President and CEO of Biocytogen. “We’ve been dedicated to expanding
the possibilities of antibody-based therapeutics in disease
treatment, through the exploration of new types of targets and
modalities through Project Integrum. The combination of
Biocytogen’s strength in antibody development with ADC
Therapeutics’ expertise and track record in payload and linker
technology may lead to the generation of novel ADC medicines for
unmet medical needs in the future.”
“We are pleased to enter this collaboration with Biocytogen as
we continue expanding our toolbox to realize the full potential of
our ADC platform,” said Patrick van Berkel, PhD, Chief Scientific
Officer of ADC Therapeutics. “We look forward to evaluating the
fully human antibodies from Biocytogen’s proprietary discovery
platform, which have the potential to accelerate the development of
our novel ADCs.”
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that
drives the research and development of novel antibody-based drugs
with innovative technologies. Using its proprietary RenMabTM
/RenLite® mice platforms for fully human monoclonal and bispecific
antibody development, Biocytogen has integrated its in vivo drug
efficacy screening platforms and strong clinical development
expertise to streamline the entire drug development process.
Biocytogen is undertaking a large-scale project to develop
first-in-class and/or best-in-class antibody drugs for more than
1000 targets, known as Project Integrum (RenMiceTM HiTS Platform).
This project has resulted in 28 drug co-development agreements and
16 RenMiceTM licensing agreements with companies around the world,
including several partnerships with multinational pharmaceutical
companies (MNCs). The company's pipeline includes 12 core products,
among which two products are in phase II multi-regional clinical
trials and two products are in phase I. Headquartered in Beijing,
Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA
and Heidelberg, Germany. For more information, please visit
http://en.biocytogen.com.cn.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage
biotechnology company improving the lives of those affected by
cancer with its next-generation, targeted antibody drug conjugates
(ADCs). The Company is advancing its proprietary PBD-based ADC
technology to transform the treatment paradigm for patients with
hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab
tesirine-lpyl) is approved by the FDA for the treatment of relapsed
or refractory diffuse large b-cell lymphoma after two or more lines
of systemic therapy. ZYNLONTA is also in development in combination
with other agents. In addition to ZYNLONTA, ADC Therapeutics has
multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and
has operations in London, the San Francisco Bay Area and New
Jersey. For more information, please visit
https://adctherapeutics.com/ and follow the Company on Twitter and
LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
ADC Therapeutics Forward-Looking Statements
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business and commercialization strategy, market
opportunities, products and product candidates, research pipeline,
ongoing and planned preclinical studies and clinical trials,
regulatory submissions and approvals, projected revenues and
expenses and the timing of revenues and expenses, timing and
likelihood of success, as well as plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements are based on our management’s beliefs
and assumptions and on information currently available to our
management. Such statements are subject to risks and uncertainties,
and actual results may differ materially from those expressed or
implied in the forward-looking statements due to various factors,
including those described in our filings with the U.S. Securities
and Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this document speak only as of the date of this press release.
We expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221128005475/en/
Biocytogen’s Contacts Antibody Assets and Platforms:
BD-Licensing@biocytogen.com Media: pr@bbctg.com.cn
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Apr 2023 to Apr 2024